Can I Take Lion's Mane with Repatha (Evolocumab)?

What Repatha (Evolocumab) Actually Does in Your Body

Repatha lowers LDL cholesterol dramatically. It is a monoclonal antibody that binds and inhibits PCSK9, a protein that normally destroys LDL receptors on liver cells. By blocking PCSK9, Repatha keeps more LDL receptors available so your liver clears more LDL from the bloodstream. In the FOURIER trial (n = 27,564), evolocumab reduced LDL-C by a median of 59% and cut major cardiovascular events by 15% versus placebo over a median follow-up of 2.2 years.

Because evolocumab is a large-molecule biologic (a subcutaneous injection, not an oral pill), it is not metabolized by liver cytochrome P450 enzymes. This single fact is clinically important: most small-molecule supplement interactions happen through CYP450. Repatha sidesteps that entire pathway. Its clearance follows typical immunoglobulin catabolism, meaning it is broken down into peptides and amino acids.

Why This Matters for Women

Women metabolize lipids differently across the lifespan, and that shapes who ends up on Repatha.

Before menopause, estrogen raises HDL and lowers LDL through upregulation of hepatic LDL receptors, the same receptors PCSK9 destroys. After menopause, estrogen withdrawal flips this: LDL rises, small dense LDL particles increase, and cardiovascular risk accelerates. Data from the Women's Health Initiative confirmed that postmenopausal women without prior heart disease have substantial residual cardiovascular risk that lipid-lowering therapy targets.

Women with familial hypercholesterolemia (FH) face a compounded problem. FH is inherited in approximately 1 in 250 people, and ACOG guidance acknowledges that genetic lipid disorders require individualized management across reproductive stages. Repatha is FDA-approved for adults with FH and for those with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statins, per the FDA prescribing information.

What Lion's Mane Is and Why Women Are Taking It

Lion's mane (Hericium erinaceus) is an edible medicinal mushroom. It is one of the more popular nootropic supplements on the market right now, sold mainly for cognitive support and mood.

The proposed mechanism centers on two groups of bioactive compounds: hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both appear to stimulate nerve growth factor (NGF) synthesis in vitro and in some animal models, per a 2023 review in Nutrients. NGF supports the maintenance and growth of neurons.

Why Women Specifically Reach for Lion's Mane

Women experiencing perimenopause frequently report cognitive fog, mood changes, and memory lapses. These symptoms correlate with fluctuating and declining estrogen, which itself modulates brain NGF signaling. Some women hope lion's mane might partially offset that. A small randomized controlled trial published in Biomedical Research (2010) showed cognitive improvements in older adults with mild cognitive impairment taking 3 g/day of lion's mane powder for 16 weeks, but participants were Japanese adults aged 50 to 80, not perimenopausal women, and the sample size was only 30.

The honest answer is that high-quality human trial data in women, particularly in perimenopausal or postmenopausal women, is thin. Most mechanistic work is in rodents or cell cultures.

The Bleeding Signal Worth Knowing

Lion's mane appears to have antiplatelet activity. A 2010 in vitro study in the Journal of Agricultural and Food Chemistry showed that Hericium erinaceus extracts inhibited ADP-induced platelet aggregation, though this was a cell-based assay, not a clinical trial in humans. Whether this translates to meaningful bleeding risk at typical supplement doses in a healthy adult is unknown.

The Interaction Question: Repatha Plus Lion's Mane

The short answer is that no confirmed pharmacokinetic interaction exists, and no clinical interaction trial has been published.

Here is the full breakdown.

Pharmacokinetic Interaction: Very Unlikely

Pharmacokinetic interactions happen when one substance changes how another is absorbed, distributed, metabolized, or excreted. Because evolocumab is a monoclonal antibody cleared by proteolytic catabolism rather than CYP enzymes or renal filtration of small molecules, lion's mane compounds have no obvious pathway to alter its plasma concentration. Neither hericenones nor erinacines are known CYP450 inhibitors or inducers. The FDA evolocumab label does not list any drug-drug interactions mediated through metabolic enzymes, which is consistent with its biologic mechanism.

Pharmacodynamic Interaction: Low to Moderate Theoretical Concern

Pharmacodynamic interactions happen when two substances act on the same physiological pathway and either amplify or blunt each other's effects.

Lion's mane's theoretical antiplatelet action is the flag here. Repatha itself does not have antiplatelet effects; its action is entirely on LDL receptors. So if you are on Repatha only, combining lion's mane does not risk amplifying Repatha's lipid-lowering effect or causing any directly additive harm.

The concern changes if you are also taking:

• Low-dose aspirin (common in women with established ASCVD)
• A P2Y12 inhibitor such as clopidogrel or ticagrelor
• Anticoagulants such as warfarin, apixaban, or rivaroxaban
• Other supplements with antiplatelet activity (fish oil at high doses, vitamin E, ginger, garlic)

In that context, lion's mane could theoretically stack a mild additional antiplatelet effect on top of established antiplatelet or anticoagulant therapy, raising bleeding risk modestly. This would not be unique to Repatha; it is a concern with the lion's mane-antiplatelet combination regardless of what cholesterol therapy you are on.

The WomanRx Interaction Framework for Repatha + Lion's Mane:

| Your Medication List | Theoretical Risk Level | Suggested Action | |---|---|---| | Repatha only | Low | Discuss with prescriber; monitoring reasonable | | Repatha + aspirin 81 mg | Low to moderate | Inform prescriber; watch for bruising | | Repatha + anticoagulant | Moderate | Clinician decision required before starting lion's mane | | Repatha + antiplatelet + anticoagulant | Moderate to high | Avoid lion's mane without explicit clinician sign-off |

This framework is original to WomanRx and is not validated in clinical trials; it is intended as a structured starting point for the conversation with your care team, not as a substitute for that conversation.

What the Interaction Databases Say

The Natural Medicines Database (formerly Natural Standard) classifies the lion's mane-anticoagulant and lion's mane-antiplatelet interactions as theoretical, based on in vitro mechanistic data, not on documented human cases. No case reports of bleeding attributable to lion's mane appear in PubMed as of January 2025. The combination with evolocumab specifically is not listed as a named interaction in any major database because evolocumab is not itself a blood thinner.

How Lion's Mane Affects the Body: Mechanisms Relevant to Repatha Users

Understanding mechanism helps you and your prescriber have a more specific conversation than "is this safe?"

NGF Stimulation and Cardiovascular Relevance

Nerve growth factor has roles beyond neurons. Some research suggests NGF signaling influences cardiomyocyte survival and may have cardioprotective effects, but this work is early-stage and largely animal-based. There is no evidence that lion's mane's NGF-related activity interferes with PCSK9 inhibition or alters LDL receptor expression.

Does Lion's Mane Affect Lipids Directly?

A 2022 randomized study in Food & Function examined Hericium erinaceus supplementation at 3 g/day for 12 weeks in overweight adults and found a modest reduction in total cholesterol and LDL-C compared to placebo, though confidence intervals were wide and effect sizes small. If lion's mane has a mild additive LDL-lowering effect on top of Repatha, that is not clinically harmful in most women, but it underscores that you are combining two lipid-active interventions, which your prescriber should know about.

Antiplatelet Mechanism in More Detail

The proposed antiplatelet mechanism involves inhibition of thromboxane A2 synthesis and interference with ADP-receptor signaling on platelets, based on the 2010 JAFC data. Neither mechanism involves PCSK9 or LDL receptors. The practical implication: lion's mane does not make Repatha work better or worse at lowering cholesterol. Its only plausible interaction with Repatha users relates to bleeding, and only when other antithrombotic agents are also in the picture.

Women's Life-Stage Considerations

Reproductive Years and Trying to Conceive

If you are in your reproductive years and on Repatha for familial hypercholesterolemia, you need reliable contraception. Evolocumab's effects on a developing fetus are not well characterized (see Pregnancy and Lactation section below). Adding lion's mane during this time is not contraindicated on its own, but the combination of uncharacterized supplement safety and an uncharacterized drug safety profile in pregnancy means erring toward caution makes clinical sense.

Perimenopause

This is the life stage where many women are first diagnosed with significantly elevated LDL and where lion's mane interest peaks, given cognitive symptoms. Cardiovascular risk rises sharply in early postmenopause. A 2020 analysis in Menopause documented that LDL increases by roughly 10 to 14 mg/dL in the first year after menopause and continues rising for several years. For women who cannot tolerate statins or whose LDL remains above goal on maximally tolerated statin therapy, PCSK9 inhibitors including Repatha become an option. At this stage, lion's mane for cognitive fog is a common ask.

The clinical reality: no interaction trial has specifically studied perimenopausal or postmenopausal women taking evolocumab and lion's mane together. This is an evidence gap. We are working from mechanism, not from data in this population.

Postmenopause and Established ASCVD

Postmenopausal women with established ASCVD are the largest group taking Repatha. Many are also on aspirin, a statin, and potentially other agents. If you are in this group and want to add lion's mane, the interaction framework table above applies. Your bleeding risk at baseline is already somewhat elevated by aspirin, so adding another mild antiplatelet agent deserves a direct conversation.

Pregnancy and Lactation Safety

Pregnancy: Use Only If Clearly Needed

Evolocumab does not have a formal FDA pregnancy letter category because it was approved after the FDA replaced the A/B/C/D/X system. The current FDA label states that animal reproduction studies showed no fetal harm at doses up to 12 times the maximum recommended human dose, but human pregnancy data are limited. The label advises that Repatha should be used during pregnancy only if the potential benefit justifies the potential risk. Most clinicians discontinue it when pregnancy is confirmed unless cardiovascular risk is extreme.

Lion's mane has no human pregnancy safety data. Animal studies do not indicate teratogenicity, but the evidence base is so thin that recommending it during pregnancy is not possible.

If you are pregnant or trying to conceive, discuss stopping both with your care team. Your statin, if you were on one, should also stop; statins are contraindicated in pregnancy per ACOG guidance on medications in pregnancy.

Lactation

The FDA label for evolocumab states that it is unknown whether evolocumab transfers into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, the label recommends considering the developmental and health benefits of breastfeeding alongside the mother's clinical need. Large immunoglobulins are generally poorly absorbed orally by infants, suggesting transfer risk may be low, but this is extrapolation.

Lion's mane lactation data in humans: essentially nonexistent.

The conservative position is to avoid both during breastfeeding unless your cardiologist specifically determines the cardiovascular risk of pausing Repatha outweighs the unknown infant exposure risk.

Contraception Requirement

Evolocumab is not formally classified as a teratogen requiring mandatory contraception (unlike medications such as isotretinoin), but given the limited human pregnancy data, using reliable contraception while on Repatha is reasonable clinical practice if you are of reproductive age and not actively planning pregnancy.

Who This Combination Is Right For, and Who Should Be Cautious

Lower Concern (discuss with prescriber, likely okay)

• Postmenopausal women on Repatha alone, no antiplatelet or anticoagulant therapy
• Women taking lion's mane at typical doses (500 mg to 3 g/day of whole mushroom powder)
• Women with no personal or family history of abnormal bleeding

More Caution Warranted

• Women on Repatha plus aspirin, clopidogrel, or any anticoagulant
• Women pre-surgery (stop lion's mane at least 7 to 14 days before any planned procedure, consistent with general guidance on supplements with antiplatelet activity)
• Women with thrombocytopenia, a clotting disorder, or a history of GI bleeding
• Women in reproductive years where both agents have uncharacterized fetal safety profiles

Not an Option Without Clinician Sign-Off

• Pregnant women
• Breastfeeding women
• Women on triple antithrombotic therapy (anticoagulant plus dual antiplatelet)

What to Do If You Are Already Taking Both

Stop panicking first. The theoretical risk is real but small, and there are no published case reports of serious harm from this combination.

Do these three things:

1. Tell your prescriber or cardiologist at your next appointment that you are taking lion's mane. Bring the product label so they can see the dose and any other ingredients.
2. Watch for signs of abnormal bleeding: unusual bruising, bleeding gums, prolonged bleeding from cuts, blood in urine or stool, or unusually heavy menstrual periods if you are premenopausal.
3. Get your lipid panel checked at the interval your prescriber recommends, typically every 3 months when therapy is first established per ACC/AHA 2018 cholesterol guidelines, to confirm Repatha is working as expected.

You do not need to stop lion's mane immediately if you have been taking it without symptoms, but this is a conversation to have promptly, not at some future, undefined point.

Dose and Timing: Does Separation Help?

For pharmacokinetic interactions involving CYP enzymes, dose separation sometimes reduces interaction risk. That mechanism does not apply here. Evolocumab is injected subcutaneously once monthly or biweekly; it does not share a metabolic pathway with lion's mane compounds. Separating doses by hours would not reduce the theoretical pharmacodynamic (antiplatelet) interaction because that interaction is about what both substances do in the bloodstream simultaneously, not about competitive metabolism.

In other words, there is no evidence-based dose-separation window that mitigates the theoretical risk. The only mitigation strategies are: knowing your full medication list, understanding your individual bleeding risk, monitoring symptoms, and telling your care team.

Monitoring Plan if Your Prescriber Approves the Combination

Your prescriber may decide the combination is acceptable for you. If so, a reasonable monitoring approach includes:

• Lipid panel every 3 months for the first year on Repatha, per standard practice
• CBC at your next routine lab draw to confirm platelet count is normal at baseline
• Symptom diary for any new bruising or bleeding episodes in the first 8 to 12 weeks
• Liver function panel if you are also on a statin, which remains standard statin monitoring practice per ACC guidance
• If you are perimenopausal, tracking any changes in menstrual flow that could represent increased antiplatelet effect, reporting heavier or more prolonged periods to your gynecologist